Literature DB >> 35612586

Newer glucose-lowering drugs and risk of dementia: A meta-analysis of cardiovascular outcome trials.

Huilin Tang1, Shu Niu1, Joshua Brown1,2, Jingkai Wei3, Hui Shao1,2, Jiang Bian4, Jingchuan Guo1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35612586      PMCID： PMC9489613          DOI： 10.1111/jgs.17895

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN： 0002-8614            Impact factor:   7.538


× No keyword cloud information.
  10 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

Authors:  Michael J Bradburn; Jonathan J Deeks; Jesse A Berlin; A Russell Localio
Journal:  Stat Med       Date:  2007-01-15       Impact factor: 2.373

Review 3.  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Authors:  Despoina Vasilakou; Thomas Karagiannis; Eleni Athanasiadou; Maria Mainou; Aris Liakos; Eleni Bekiari; Maria Sarigianni; David R Matthews; Apostolos Tsapas
Journal:  Ann Intern Med       Date:  2013-08-20       Impact factor: 25.391

4.  Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.

Authors:  Jian-Bo Zhou; Xingyao Tang; Min Han; Jinkui Yang; Rafael Simó
Journal:  Metabolism       Date:  2020-05-22       Impact factor: 8.694

5.  Empirical Comparison of Publication Bias Tests in Meta-Analysis.

Authors:  Lifeng Lin; Haitao Chu; Mohammad Hassan Murad; Chuan Hong; Zhiyong Qu; Stephen R Cole; Yong Chen
Journal:  J Gen Intern Med       Date:  2018-04-16       Impact factor: 5.128

Review 6.  Pathophysiological Mechanisms Linking Type 2 Diabetes and Dementia: Review of Evidence from Clinical, Translational and Epidemiological Research.

Authors:  Omar Yaxmehen Bello-Chavolla; Neftali Eduardo Antonio-Villa; Arsenio Vargas-Vázquez; José Alberto Ávila-Funes; Carlos Alberto Aguilar-Salinas
Journal:  Curr Diabetes Rev       Date:  2019

7.  Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

Authors:  Deepak L Bhatt; Michael Szarek; Bertram Pitt; Christopher P Cannon; Lawrence A Leiter; Darren K McGuire; Julia B Lewis; Matthew C Riddle; Silvio E Inzucchi; Mikhail N Kosiborod; David Z I Cherney; Jamie P Dwyer; Benjamin M Scirica; Clifford J Bailey; Rafael Díaz; Kausik K Ray; Jacob A Udell; Renato D Lopes; Pablo Lapuerta; P Gabriel Steg
Journal:  N Engl J Med       Date:  2020-11-16       Impact factor: 91.245

8.  Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study.

Authors:  Ida Kim Wium-Andersen; Merete Osler; Martin Balslev Jørgensen; Jørgen Rungby; Marie Kim Wium-Andersen
Journal:  Eur J Endocrinol       Date:  2019-11       Impact factor: 6.664

9.  Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment.

Authors:  Huilin Tang; Stephen E Kimmel; Inmaculada Hernandez; Maria M Brooks; Kenneth Cusi; Steven M Smith; Weilong Shi; Almut G Winterstein; Jared W Magnani; Jingchuan Guo
Journal:  Diabetes Obes Metab       Date:  2021-09-20       Impact factor: 6.577

Review 10.  Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.

Authors:  Shaker A Mousa; Bassam M Ayoub
Journal:  Neural Regen Res       Date:  2019-05       Impact factor: 5.135
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.